Loading…
Monday September 30, 2024 1:45pm - 2:30pm EDT
This panel will explore the advancements in CAR T-cell therapies, RNA therapeutics, and complex biologics—therapies that offer opportunities to address unmet medical needs. However, the path from drug discovery to commercial manufacturing for these treatments is anything but straightforward. Traditional research and large-scale manufacturing methods, designed for small molecules, fall short of meeting the unique demands of these innovative therapies. Learn how these advancements are speeding up the research process and bringing innovative treatments to the clinic and market faster, particularly in personalized medicine.
  • Discover the unique challenges of developing complex therapies like RNA-based drugs and gene therapies, and how companies are overcoming these obstacles to deliver new therapies for patients.
  • Assess how genetics-driven insights are revolutionizing lab processes and accelerating drug discovery and development.
  • Identify strategies for optimizing and streamlining the drug development process, from discovery through the clinic and manufacturing and how to improve your process as it evolves during development.
  • Establish the importance of partnerships and innovative thinking in overcoming challenges and advancing new therapies and hear examples of successful collaborations within the lab
Moderators
avatar for Sophia Lugo

Sophia Lugo

CEO, Chairman and Co-Founder, Radar Therapeutics
Sophia Lugo is CEO, Chairman, and Co-Founder at Radar Therapeutics, an mRNA therapeutics company based in Berkeley, California. Before Radar, Sophia held strategy and product roles at BGI Genomics’ Health Division and Ventures Incubator, the Boston Consulting Group, the US Surgeon... Read More →
Speakers
avatar for Christian Lawrence

Christian Lawrence

Sr. Director of Manager Research Centers, SmartLabs
Christian Lawrence is a scientist and administrator with over 20 years of experience in research operations and management. The bulk of this time (2008-2021) was spent at Boston Children’s Hospital (BCH), where he built and managed specialized laboratories and programs to drive... Read More →
avatar for David Eavarone

David Eavarone

Head Director of Lab/Screening, Absci
David Eavarone, PhD, Head of Lab and Screening, Absci. David has over a decade of experience leading the development of antibody-based therapeutics. He played a key role in engineering clinical-stage biologics against infectious disease targets at Visterra Inc and oncology targets... Read More →
avatar for Jennifer Low, M.D., Ph.D.

Jennifer Low, M.D., Ph.D.

Head of Therapeutics Development, 23andMe
Jennifer Low, MD, PhD, is the Head of Therapeutics Development at 23andMe. She oversees the transition of potential therapeutics from 23andMe's research laboratories into clinical development studies, and leads a group that includes preclinical and clinical development and drug manufacturing.Jennifer... Read More →
Monday September 30, 2024 1:45pm - 2:30pm EDT
The Westin Boston Seaport District

Log in to save this to your schedule, view media, leave feedback and see who's attending!

Share Modal

Share this link via

Or copy link